- Financial Performance
- 1 min read
Natco Pharma's net profit zooms 31 percent to Rs 420 Cr in Q1
The company had made a provision of Rs 51 crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about Rs 17.0 crore towards special incentive to employees during the quarter.
The company had made a provision of Rs 51 crore towards pending patent infringement litigation cases for its products in India (without admission of either liability for infringement or validity of such patents) and also incurred about Rs 17.0 crore towards special incentive to employees during the quarter.
Major drivers of business during the quarter were from formulation exports, strong growth in domestic business of both Pharma and Agro, and steady sales from subsidiaries, Natco said adding the Board of Directors has declared an interim dividend of Rs 7 (350 per cent) per equity share of Rs 2 each, for the current fiscal.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions